Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease

Detalhes bibliográficos
Autor(a) principal: Deuzilane Muniz Nunes
Data de Publicação: 2007
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFC
Texto Completo: http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=1215
Resumo: Disturbed sleep is in common Chronic Obstructive Pulmonary Disease (COPD). Conventional hypnotics worsen nocturnal hypoxemia and can lead to respiratory failure in severe cases of this condition. Melatonin administration has been reported to ameliorate sleep problems in several clinical conditions and is generally considered to be safe. The aim of this study was to evaluate the effect of 21 days of melatonin administration on subjective sleep quality in ambulatory patients with clinically stable COPD. This was a randomized, double-blind, placebo-controlled study on the effects of melatonin on sleep in COPD. Twenty-five patients with moderate to very severe COPD were randomized to receive either melatonin 3 mg (n=12) or placebo (n=13) for 21 days. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI); daytime sleepiness was measured by the Epworth Sleepiness Scale (ESS); life quality was assessed by St. Georgeâs Respiratory Questionnaire (SGRQ); pulmonary function and functional exercise level were assessed, respectively, by spirometry and the six-minute walk test. These tests were repeated at the end of the treatment for comparison. Sixteen patients (64%) presented poor-quality sleep on initial evaluation. Melatonin treatment significantly improved sleep (p= 0.012). No changes in daytime sleepiness, quality of life, lung function and functional exercise level were observed. We conclude that melatonin can improve subjective sleep quality in COPD. Further studies into the safety of long-term melatonin use are needed before it can be recommended for the management of sleep disturbances in these patients
id UFC_7fe2a0a505c97964e88f7ce9d77d465c
oai_identifier_str oai:www.teses.ufc.br:973
network_acronym_str UFC
network_name_str Biblioteca Digital de Teses e Dissertações da UFC
spelling info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisClinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary diseaseEstudo clÃnico dos efeitos da melatonina sobre a qualidade do sono e a funÃÃo pulmonar obstrutiva crÃnica2007-12-07Pedro Felipe Carvalhedo de Bruin19463855300Mirian Parente Monteiro15507645353Eanes Delgado Barros Pereira2473100535395712526387http://buscatextual.cnpq.br/buscatextual/visualizacv.jsp?id=K4775230T2Deuzilane Muniz NunesUniversidade Federal do CearÃPrograma de PÃs-GraduaÃÃo em CiÃncias FarmacÃuticasUFCBRFARMACIADisturbed sleep is in common Chronic Obstructive Pulmonary Disease (COPD). Conventional hypnotics worsen nocturnal hypoxemia and can lead to respiratory failure in severe cases of this condition. Melatonin administration has been reported to ameliorate sleep problems in several clinical conditions and is generally considered to be safe. The aim of this study was to evaluate the effect of 21 days of melatonin administration on subjective sleep quality in ambulatory patients with clinically stable COPD. This was a randomized, double-blind, placebo-controlled study on the effects of melatonin on sleep in COPD. Twenty-five patients with moderate to very severe COPD were randomized to receive either melatonin 3 mg (n=12) or placebo (n=13) for 21 days. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI); daytime sleepiness was measured by the Epworth Sleepiness Scale (ESS); life quality was assessed by St. Georgeâs Respiratory Questionnaire (SGRQ); pulmonary function and functional exercise level were assessed, respectively, by spirometry and the six-minute walk test. These tests were repeated at the end of the treatment for comparison. Sixteen patients (64%) presented poor-quality sleep on initial evaluation. Melatonin treatment significantly improved sleep (p= 0.012). No changes in daytime sleepiness, quality of life, lung function and functional exercise level were observed. We conclude that melatonin can improve subjective sleep quality in COPD. Further studies into the safety of long-term melatonin use are needed before it can be recommended for the management of sleep disturbances in these patients AlteraÃÃes do sono sÃo comuns na DoenÃa Pulmonar Obstrutiva CrÃnica (DPOC). HipnÃticos convencionais pioram a hipoxemia noturna e podem conduzir a insuficiÃncia respiratÃria em pacientes com DPOC grave. Tem-se relatado que a administraÃÃo de melatonina (MLT) melhora o sono em vÃrias condiÃÃes clÃnicas e à considerada segura. O objetivo deste estudo foi avaliar os efeitos da administraÃÃo noturna de MLT por 21 dias sobre a qualidade subjetiva do sono, a sonolÃncia diurna e a funÃÃo pulmonar em pacientes com DPOC. O estudo foi randomizado, duplo-cego, controlado por placebo. Vinte e cinco portadores de DPOC clinicamente estÃvel, em acompanhamento ambulatorial regular, foram avaliados quanto a qualidade de sono pelo Ãndice de Qualidade de Sono de Pittsburgh (IQPS); sonolÃncia diurna, pela Escala de SonolÃncia de Epworth (ESE); qualidade de vida, pelo QuestionÃrio RespiratÃrio do Hospital Saint George; funÃÃo pulmonar e nÃvel funcional de exercÃcio, respectivamente, por espirometria e teste de caminhada de seis minutos. Em seguida, os pacientes foram alocados para tratamento com MLT 3 mg/d (n=12) ou placebo (n=13). Ao final do tratamento, os testes foram repetidos para comparaÃÃo. Na avaliaÃÃo inicial, 16 pacientes (64%) apresentaram sono de mÃ-qualidade (IQSP > 5). O uso de melatonina melhorou significantemente a qualidade subjetiva do sono (p= 0.012) particularmente, os aspectos latÃncia do sono (p=0.008) e a duraÃÃo do sono (p=0.046). Nenhuma mudanÃa significante foi observada no grau de sonolÃncia diurna, na qualidade de vida, na funÃÃo pulmonar e no nÃvel funcional de exercÃcio. Em conclusÃo, a melatonina melhora a qualidade do sono em pacientes com DPOC. Estudos adicionais sobre a seguranÃa da utilizaÃÃo a longo prazo de melatonina sÃo necessÃrios antes que esta substÃncia possa ser recomendada com seguranÃa nestes pacientes.FundaÃÃo Cearense de Apoio ao Desenvolvimento Cientifico e TecnolÃgicohttp://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=1215application/pdfinfo:eu-repo/semantics/openAccessporreponame:Biblioteca Digital de Teses e Dissertações da UFCinstname:Universidade Federal do Cearáinstacron:UFC2019-01-21T11:14:06Zmail@mail.com -
dc.title.en.fl_str_mv Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
dc.title.alternative.pt.fl_str_mv Estudo clÃnico dos efeitos da melatonina sobre a qualidade do sono e a funÃÃo pulmonar obstrutiva crÃnica
title Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
spellingShingle Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
Deuzilane Muniz Nunes
FARMACIA
title_short Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
title_full Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
title_fullStr Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
title_full_unstemmed Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
title_sort Clinical study of melatonin effects about sleep quality and pulmonary function in chronic obstructive pulmonary disease
author Deuzilane Muniz Nunes
author_facet Deuzilane Muniz Nunes
author_role author
dc.contributor.advisor1.fl_str_mv Pedro Felipe Carvalhedo de Bruin
dc.contributor.advisor1ID.fl_str_mv 19463855300
dc.contributor.referee1.fl_str_mv Mirian Parente Monteiro
dc.contributor.referee1ID.fl_str_mv 15507645353
dc.contributor.referee2.fl_str_mv Eanes Delgado Barros Pereira
dc.contributor.referee2ID.fl_str_mv 24731005353
dc.contributor.authorID.fl_str_mv 95712526387
dc.contributor.authorLattes.fl_str_mv http://buscatextual.cnpq.br/buscatextual/visualizacv.jsp?id=K4775230T2
dc.contributor.author.fl_str_mv Deuzilane Muniz Nunes
contributor_str_mv Pedro Felipe Carvalhedo de Bruin
Mirian Parente Monteiro
Eanes Delgado Barros Pereira
dc.subject.cnpq.fl_str_mv FARMACIA
topic FARMACIA
dc.description.sponsorship.fl_txt_mv FundaÃÃo Cearense de Apoio ao Desenvolvimento Cientifico e TecnolÃgico
dc.description.abstract.por.fl_txt_mv Disturbed sleep is in common Chronic Obstructive Pulmonary Disease (COPD). Conventional hypnotics worsen nocturnal hypoxemia and can lead to respiratory failure in severe cases of this condition. Melatonin administration has been reported to ameliorate sleep problems in several clinical conditions and is generally considered to be safe. The aim of this study was to evaluate the effect of 21 days of melatonin administration on subjective sleep quality in ambulatory patients with clinically stable COPD. This was a randomized, double-blind, placebo-controlled study on the effects of melatonin on sleep in COPD. Twenty-five patients with moderate to very severe COPD were randomized to receive either melatonin 3 mg (n=12) or placebo (n=13) for 21 days. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI); daytime sleepiness was measured by the Epworth Sleepiness Scale (ESS); life quality was assessed by St. Georgeâs Respiratory Questionnaire (SGRQ); pulmonary function and functional exercise level were assessed, respectively, by spirometry and the six-minute walk test. These tests were repeated at the end of the treatment for comparison. Sixteen patients (64%) presented poor-quality sleep on initial evaluation. Melatonin treatment significantly improved sleep (p= 0.012). No changes in daytime sleepiness, quality of life, lung function and functional exercise level were observed. We conclude that melatonin can improve subjective sleep quality in COPD. Further studies into the safety of long-term melatonin use are needed before it can be recommended for the management of sleep disturbances in these patients
AlteraÃÃes do sono sÃo comuns na DoenÃa Pulmonar Obstrutiva CrÃnica (DPOC). HipnÃticos convencionais pioram a hipoxemia noturna e podem conduzir a insuficiÃncia respiratÃria em pacientes com DPOC grave. Tem-se relatado que a administraÃÃo de melatonina (MLT) melhora o sono em vÃrias condiÃÃes clÃnicas e à considerada segura. O objetivo deste estudo foi avaliar os efeitos da administraÃÃo noturna de MLT por 21 dias sobre a qualidade subjetiva do sono, a sonolÃncia diurna e a funÃÃo pulmonar em pacientes com DPOC. O estudo foi randomizado, duplo-cego, controlado por placebo. Vinte e cinco portadores de DPOC clinicamente estÃvel, em acompanhamento ambulatorial regular, foram avaliados quanto a qualidade de sono pelo Ãndice de Qualidade de Sono de Pittsburgh (IQPS); sonolÃncia diurna, pela Escala de SonolÃncia de Epworth (ESE); qualidade de vida, pelo QuestionÃrio RespiratÃrio do Hospital Saint George; funÃÃo pulmonar e nÃvel funcional de exercÃcio, respectivamente, por espirometria e teste de caminhada de seis minutos. Em seguida, os pacientes foram alocados para tratamento com MLT 3 mg/d (n=12) ou placebo (n=13). Ao final do tratamento, os testes foram repetidos para comparaÃÃo. Na avaliaÃÃo inicial, 16 pacientes (64%) apresentaram sono de mÃ-qualidade (IQSP > 5). O uso de melatonina melhorou significantemente a qualidade subjetiva do sono (p= 0.012) particularmente, os aspectos latÃncia do sono (p=0.008) e a duraÃÃo do sono (p=0.046). Nenhuma mudanÃa significante foi observada no grau de sonolÃncia diurna, na qualidade de vida, na funÃÃo pulmonar e no nÃvel funcional de exercÃcio. Em conclusÃo, a melatonina melhora a qualidade do sono em pacientes com DPOC. Estudos adicionais sobre a seguranÃa da utilizaÃÃo a longo prazo de melatonina sÃo necessÃrios antes que esta substÃncia possa ser recomendada com seguranÃa nestes pacientes.
description Disturbed sleep is in common Chronic Obstructive Pulmonary Disease (COPD). Conventional hypnotics worsen nocturnal hypoxemia and can lead to respiratory failure in severe cases of this condition. Melatonin administration has been reported to ameliorate sleep problems in several clinical conditions and is generally considered to be safe. The aim of this study was to evaluate the effect of 21 days of melatonin administration on subjective sleep quality in ambulatory patients with clinically stable COPD. This was a randomized, double-blind, placebo-controlled study on the effects of melatonin on sleep in COPD. Twenty-five patients with moderate to very severe COPD were randomized to receive either melatonin 3 mg (n=12) or placebo (n=13) for 21 days. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI); daytime sleepiness was measured by the Epworth Sleepiness Scale (ESS); life quality was assessed by St. Georgeâs Respiratory Questionnaire (SGRQ); pulmonary function and functional exercise level were assessed, respectively, by spirometry and the six-minute walk test. These tests were repeated at the end of the treatment for comparison. Sixteen patients (64%) presented poor-quality sleep on initial evaluation. Melatonin treatment significantly improved sleep (p= 0.012). No changes in daytime sleepiness, quality of life, lung function and functional exercise level were observed. We conclude that melatonin can improve subjective sleep quality in COPD. Further studies into the safety of long-term melatonin use are needed before it can be recommended for the management of sleep disturbances in these patients
publishDate 2007
dc.date.issued.fl_str_mv 2007-12-07
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
status_str publishedVersion
format masterThesis
dc.identifier.uri.fl_str_mv http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=1215
url http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=1215
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.publisher.program.fl_str_mv Programa de PÃs-GraduaÃÃo em CiÃncias FarmacÃuticas
dc.publisher.initials.fl_str_mv UFC
dc.publisher.country.fl_str_mv BR
publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFC
instname:Universidade Federal do Ceará
instacron:UFC
reponame_str Biblioteca Digital de Teses e Dissertações da UFC
collection Biblioteca Digital de Teses e Dissertações da UFC
instname_str Universidade Federal do Ceará
instacron_str UFC
institution UFC
repository.name.fl_str_mv -
repository.mail.fl_str_mv mail@mail.com
_version_ 1643295117612679168